Dexcom (DXCM) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Dexcom (DXCM)

72.43

-0.04 (0.06%)

as of Jun 18, 2026, 10:37:55 pm Market Open.

10 watching

BUY ON WEAKNESS

Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

DXCM has been hit hard as investors fear new success of weight loss drugs will reduce demand for diabetes monitoring products. DXCM is not alone in the decline. But it is still growing, and recent comments by analysts suggest the sell off is quite overdone. It has new products on tap and is strong financially. Market share remains robust. Best Buy has started selling its products (not material on its own, but shows an expanding footprint). We would see DXCM as worth holding. Because it is 33X as large was WELL, they are hard to compare. WELL, being smaller, could potentially rise more, but comes with much more overall risk. From a safety and valuation standpoint, we would, today, prefer DXCM.
Unlock Premium - Try 5i Free

DON'T BUY

Does well when (sadly) diabetes is booming. The fear is that drugs develop from Novo Nordisk and Eli Lilly will cut down on diabetes. He tends to agree. Be careful here.

DON'T BUY

The Saudi/OPEC oil cut today

He regrets he didn't sell some of his oil holdings today. He doesn't see the price of oil moving up from here, but will move down.

COMMENT

Shares are expensive, but their diabetes machine is the best. Likes it, but these expensive stocks have had a hard time in this market.

COMMENT

They make blood sugar monitors used by diabetics. One of the best growth stocks of the last 5 years, from $60 from end-2017 to $659 last November. Since then, it's plunged to $462. Today, the company reported Q4 sales were in line and issued cautious guidance for 2022. They under-promise and over-delivered.

BUY

They make blood-sugar monitor for diabetics. He has long liked this. Performed well last year until Covid delayed the development in their new device which happened when the market lost interest in health stocks. But a few months ago, it started to come back. Yesterday, they reported a mixed quarter with a nice revenue beat, but small earnings miss, yet offered conservative guidance expand overseas. It fell 5% today. Likes that they're spending money to grow and their conservative nature.

COMMENT

The stock got overheated and has pulled back. It's up over 50% YTD. The quarter they reported in late-October was imperfect with a big earnings beat but a smaller sales beat compared to previous quarter. Their new blood sugar monitor is rolling out in only some key markets in 2021, not in all key ones until 2023. Both factors led to the stock getting hurt. Today, management guided for 15-20% growth through 2025, but fell short of expectations. The stock sold off today.

HOLD

Medical devices. Monitor diabetes. Recurring revenue from disposable sensors. M&A potential. Really likes the sector. Stick with it.

Showing 1 to 8 of 8 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Dexcom (DXCM) Frequently Asked Questions

What is Dexcom stock symbol?

Dexcom is a American stock, trading under the symbol DXCM (previously DXCM-Q on Stockchase) on the NASDAQ (DXCM). It is usually referred to as NASDAQ:DXCM or DXCM

Is Dexcom a buy or a sell?

In the last year, no analyst issued a Buy, Sell, or Hold rating on DXCM (previously DXCM-Q on Stockchase) on Stockchase. Read the latest expert commentary for Dexcom.

Is Dexcom a good investment or a top pick?

Dexcom was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Dexcom.

Why is Dexcom stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Dexcom.

Is Dexcom worth watching?

Dexcom is followed by 10 investors on Stockchase and is a trending stock that is worth watching.

What is Dexcom stock price?

On 2026-06-18, Dexcom (DXCM) stock closed at a price of $72.43.

Most Recent Experts

Stockchase Insights

5i Research

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Dexcom (DXCM)

Dexcom(DXCM)

Dexcom(DXCM)

Dexcom(DXCM)

Dexcom(DXCM)

Dexcom(DXCM)

Dexcom(DXCM)

Dexcom(DXCM)

Dexcom(DXCM)